Esophageal Adenocarcinoma

The GLOW study is published! Kudos to the GI Oncology community and our patients. Zolbetuximab should be considered a standard option for CLDN18.2 positive gastroesophageal adenocarcinoma! @drallysonocean @pashtoonkasi @nyphospital @WCM_MeyerCancer https://t.co/G0wWPLz2Zr (@mdmanishshah)

“Evolving Landscape of Targeted Treatment Options for HER2-Positive Gastric/Gastroesophageal Adenocarcinomas” by Raisa Epistola, MD, Joseph Chao, MD, and Jennifer Lee, MD https://t.co/lPI7BsMr8o @JoeChaoMD @HarborUCLA @cityofhope (@clinadvances)

Congratulations to @RichardPTEvans on passing his PhD viva on ‘Immunotherapeutic Opportunities in Oesophageal Adenocarcinoma’ today with Birmingham University @UoBSurgery @paulmos63832199 @news_ub @unibirm_MDS Thanks to @cstarlab and @LizzySmyth1 for coming to examine! (@EwenGriffiths)

Newly diagnosed patients with Barrett esophagus have high rates of postendoscopy esophageal adenocarcinoma and postendoscopy esophageal neoplasia. Study in @AGA_Gastro. @KauppilaJoonas @nshaheenUNC #GItwitter #gastroenterology https://t.co/Ve9grXfO3G (@Gastro_Advisor)

Optimal use of systemic agents clearly key to managing systemic failures with definitive chemoradiotherapy and there has been some positive data in the neoadjuvant setting for PET-directed chemo switch in patients with oesophageal adenocarcinomas (CALGB80803 @KarynAGoodman). (@DrCMJones)

#ResearchWednesday: In a post hoc analysis @DanielLinMD & colleagues found nivolumab + chemo was associated with a gain in quality-adjusted survival compared w chemo alone in advanced esophageal adenocarcinoma & gastric & gastroesophageal junction cancers: https://t.co/NJqu59wNRm (@KimmelCancerCtr)

Live now❗️ 🎉 Drs. Elena Elimova, Geoffrey Ku, & Shubham Pant (@DrShubhamPant) discuss the evidence supporting modern targeted strategies for the management of biliary tract cancers (#BTC) & gastroesophageal adenocarcinoma (#GEA) https://t.co/uf82egUcPd #MedEd #MedTwitter #ASCO23 (@PeerView)

Watch the #GICancers experts during an #ASCO23 Live Virtual Symposium! Hear evidence supporting targeted strategies for biliary tract cancers (#BTC) and gastroesophageal adenocarcinoma (#GEA) from Drs. Elimova, Ku, & @DrShubhamPant tomorrow at 7:00 PM EDT! https://t.co/uf82egUcPd (@PeerView)

(2/2)...Nivolumab and Chemotherapy in Previously Untreated, Locally Advanced, Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma @KlempnerSam ➡️ https://t.co/I4j2RKV3WG @ASCO #MGCCatASCO23 (@MGHCancerCenter)

@giconnectInfo expert @KlempnerSam presents another intriguing poster at #ASCO23! STAR-221: #domvanalima #zimberelimab + chemotherapy vs #nivolumab + chemotherapy in locally advanced, unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. https://t.co/WREdXNkNFO (@giconnectInfo)

Watch the #GICancers experts during an #ASCO23 Live Virtual Symposium! Hear evidence supporting targeted strategies for biliary tract cancers (#BTC) and gastroesophageal adenocarcinoma (#GEA) from Drs. Elimova, Ku, & @DrShubhamPant on 6/8 at 7:00 PM EDT! https://t.co/uf82egUcPd (@PeerView)

1/2 Gastroesophageal adenocarcinoma is less common & has better outcomes in females. We investigated if this was due to expression of oestrogen receptors (ER) α and β in the GO2 trial population. @RussellPetty19 @PeterHall001 @UoDMedicine @NHSTayside https://t.co/ICCqPn6gKx (@majbaxter)

#AACR23 | Section 47 | Monday CT155 - Long Term Results and ctDNA Correlatives for CAPOX BETR: A Multi-center Phase II Trial of Capecitabine, Oxaliplatin, Bevacizumab and Trastuzumab for Previously Untreated HER2 Positive Metastatic Gastroesophageal Adenocarcinoma @KlempnerSam (@MGHCancerCenter)

The SPOTLIGHT trial shows zolbetuximab, the first claudin 18.2-targeted therapy in gastroesophageal adenocarcinomas, significantly improves OS. Added bonuses: 🔥 CLDN 18.2 expression occurs in ~35% 🔥 Cheap, easy IHC assay. https://t.co/TaCy937iqb (@SKamath_MD)

➡️We need a collaborative PD-L1 Blueprint type study in gastroesophageal adenocarcinoma to be satisfied that we are using a biomarker which is reliable and reproducible.. Watch this space @EORTC @sundar__raghav (@LizzySmyth1)

......but PD-L1 can be an unreliable biomarker in gastroesophageal adenocarcinoma (@LizzySmyth1)

🔥Claudin18.who? Examining biomarker overlap and outcomes in claudin 18.2+ g astroesophageal adenocarcinomas @ESMO_Open https://t.co/nCnUVJxTqf 👏Very nice editorial 👉Gastric cancer on the way to #PrecisionMedicine @myESMO @OncoAlert (@ArndtVogel)

Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas - ESMO Open https://t.co/nHWYnj8oor (@dralanburguete)

Now online in @ESMO_Open Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas https://t.co/udJsYpZQCF (@KlempnerSam)

#Zanidatamab, With #Biparatopic Binding to #HER2, Shows 84% OS in Phase 2 Study of #Gastroesophageal Adenocarcinoma https://t.co/lgP40S8oV2 via @AJMC (@Rndubois)

Interesting analysis of the panorama of #therapies directed at #ERBB2 overexpression in #gastroesophageal #adenocarcinoma. https://t.co/QAa93vMM8z (@Dr_Ivanoncologo)

Peri-op FLOT/Trastuzumab/Pertuzumab for resectable HER2+ Gastroesophageal Adenocarcinoma - better pCR and ypN0 rates than FLOT alone. But will it translate to improved survival given the negative JACOB trial? ⁦@JCO_ASCO⁩ https://t.co/LShAKT3iGw (@LFerri123)

If I had a hi HER2 & hi PDL1 expressing gastroesophageal adenocarcinoma, I would take a crack at this chemo free approach before moving to chemo. Oxaliplatin-related neuropathy sucks. Some pts delayed oxali use for years and some still NED several yrs later… (@DocCatenacci)

Fun to be part of this biomarker enriched strategy. @ESMO_Open @DocCatenacci @JoeChaoMD, others. @OncoAlert Margetuximab with retifanlimab as 1L tx in HER2+/PD-L1+ advanced gastroesophageal adenocarcinoma: MAHOGANY cohort A https://t.co/8McqJnddYn (@KlempnerSam)

🤔How to treat EGFR-amplified gastroesophageal adenocarcinoma? https://t.co/i7cq4JIKOP 🔥latest real world evidence! 🎯n=60 ORR 54% PFS 4.6 mOS 21 (1st) 9 (2nd) 8 (3rd) ❌KRAS, NRAS, MET, ERBB2 co-alt. = Resistance? 👉 promising, but we need to understand the pathway @myESMO (@ArndtVogel)

Timely targeted treatment initiation can be challenging because additional biomarker testing is needed. The authors hypothesized that timely targeted treatment improves survival relative to nontimely initiation in metastatic HER2+ gastroesophageal adenocarcinoma 2/4 (@VivekSubbiah)

Is it about TIME ? Association between timely targeted treatment & outcomes in patients with metastatic HER2‐overexpressing gastroesophageal adenocarcinoma 1/4 @JournalCancer @OncoAlert https://t.co/r032l26mrY (@VivekSubbiah)

Excellent review on a timely topic: Safety and efficacy of HER2 blockade by #trastuzumab -based chemotherapy-containing combination strategies in HER2+ #gastroesophageal #adenocarcinoma. Just published in ⁦@ESMO_Open⁩ by ⁦@myESMO⁩ https://t.co/RJk0l0qNmM (@cczielinski)

Very interesting. I'm happy to admit morphological criteria of dysplasia are much more difficult and subjective than assessing p53 expression. This sounds good and logical, hope it helps bringing down the incidence of esophageal adenocarcinoma. (@DraEosina)

WATCH: @DocCatenacci, of @UCCancerCenter, discusses navigating HER2 testing in gastric and gastroesophageal adenocarcinoma. #stomachcancer https://t.co/A9CUuAWOFO (@OncLive)

Excited to share a review co-authored with @RajivAgarwalMD on HER2-directed therapies for advanced gastric & gastroesophageal adenocarcinoma. https://t.co/IpOvbPeFMI @jordanberlin5 @VUMCHemOnc @VUMC_Cancer @VUMC_MedPSTP @VUMC_Medicine (@BGriebMD)

Now available - Dr. Dan Catenacci (@DocCatenacci) presents updates to FIGHT: A randomized placebo-controlled study of bemarituzumab and chemotherapy in the first line setting of FGFR2 positive gastroesophageal adenocarcinoma #ASCO21 View talk: https://t.co/FWa1xK3JlV (@UCCancerCenter)

Is #HER2 & #PDL1 testing feasible on #CirculatingTumorCells❓ 👇🏾Short answer: YES✅ (timing, system, 💰, real-time) Here’s half a dozen #CTCs from a HER2➕gastroesophageal adenocarcinoma post progression on IO+HER2+Chemo ē still HER2➕(last column) ē response to tucatinib. (@pashtoonkasi)

55 yr old man in great shape and no co-morbidities presents with T2N0M0 distal esophageal adenocarcinoma- guess what, the tumor is MSI-H. How would you treat this pt?@DocCatenacci @YJanjigianMD @JoeChaoMD @ILSONDavid @LizzySmyth1 (@doctorC369)

#AACR21 You will like this👇🏾. A different & less talked about kind of #liquidbiopsies➡️ #CirculatingTumorCells.🟣🟢🟠 #ctDNA does not give you the membrane/cellular part. With📈#HER2⛔️& PD-1/PD-L1⛔️ #immunotherapy, this’d be of value. 👀 Esophageal Adenocarcinoma👇🏾PD-L1➖, HER2➕ (@pashtoonkasi)

MET Amplification is seen in LUAD, GBM, colon adenocarcinoma, esophageal adenocarcinoma, and cutaneous melanoma. Two among numerous trials: Volitinib in Recurrent or Refractory Primary CNS Tumors (NCT03598244), Savolitinib in CRC (NCT03592641). (@anu_iris)

The combination of nivolumab plus standard-of-care chemotherapy has demonstrated groundbreaking efficacy & tolerability in patients w/ PD-L1–positive advanced gastric cancer, GEJ cancer, and esophageal adenocarcinoma. @YJanjigianMD @sloan_kettering #esocsm https://t.co/ZBzyG1j5u0 (@OncLive)

More data to support EGFR as actionable in selected GEA patients. @FilippoPietran4 @FoundationATCG @SteveMaronMD @DocCatenacci @LizzySmyth1 Optimized EGFR blockade strategies in EGFR addicted gastroesophageal adenocarcinomas https://t.co/wwI3NDxn32 (@KlempnerSam)

#GI21 You will like this👇🏾. A different & less talked about kind of #liquidbiopsies➡️ #CirculatingTumorCells.🟣🟢🟠 #ctDNA does not give you the membrane/cellular part. With 📈#HER2⛔️ & PD-1/PD-L1⛔️ #immunotherapy, this’d be of value. 👀 Esophageal Adenocarcinoma👇🏾PD-L1➖, HER2➕ (@pashtoonkasi)

#GI21 perfect timing for a new @US_FDA drug approval👇🏾. On 1st day of ASCO GI 🙌🏾 ✅Fam-trastuzumab deruxtecan-nxki (Enhertu) for locally advanced or metastatic 🎯 HER2➕ gastric or gastroesophageal adenocarcinoma who have received a prior trastuzumab-based regimen #OncoAlert. https://t.co/8JPXSbB5a1 (@pashtoonkasi)

Help me understand @KoheiShitara @agrothey. What does the priority review status entails? What are the next steps? Also, this would also be for esophageal adenocarcinoma HER2➕as well? #STCSM #ESOCSM (@pashtoonkasi)

As the Checkmate-577 #immunotherapy data reads out, see our @BigTenCRC adjuvant PD-L1⛔️(durvalumab) in #esophageal adenocarcinoma patients ē residual #cancer post chemoXRT☢️ @ASCO_pubs. 🔴37 pts 🟢Safe 🔵Median OS: 28.1m 🟣RFS: 55.5%➡️2yr #CTCs https://t.co/B1BhhpRKDu @OncoAlert (@pashtoonkasi)